86 related articles for article (PubMed ID: 2405108)
1. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.
Mavligit GM; Zukiwski AA; Gutterman JU; Salem P; Charnsangavej C; Wallace S
J Clin Oncol; 1990 Feb; 8(2):319-24. PubMed ID: 2405108
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
5. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
[TBL] [Abstract][Full Text] [Related]
6. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
[TBL] [Abstract][Full Text] [Related]
7. Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery.
Ohnishi H; Okuno K; Yasutomi M
Cancer Biother; 1993; 8(3):213-22. PubMed ID: 7804361
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
Okuno K; Ohnishi H; Koh K; Shindo H; Yoshioka H; Yasutomi M
Biotherapy; 1992; 4(4):257-65. PubMed ID: 1622739
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
10. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
11. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
[TBL] [Abstract][Full Text] [Related]
12. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
13. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
14. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
16. [Continuous arterial infusion therapy of recombinant interleukin-2 and cyclophosphamide in hepatoma and liver metastasis].
Hayakawa K; Fukushima T; Seito D; Asakura Y; Yamanaka Y; Morita T; Sasaki M; Konn M; Ono K
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2842-4. PubMed ID: 2551226
[TBL] [Abstract][Full Text] [Related]
17. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
Ishikawa T; Imawari M; Moriyama T; Ohnishi S; Matsuhashi N; Suzuki G; Takaku F
J Cancer Res Clin Oncol; 1988; 114(3):283-90. PubMed ID: 2838488
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
